Sugar Land, Texas – September 12, 2026 -- QuVa Pharma, Inc. has acquired a range of essential medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business.
QuVa to phase in acquired products starting later in 2026
QuVa expects to begin introducing selected products from the acquired portfolio in phases later in 2026, with plans to expand its offerings over the following six months. The deal covers critical medication categories including Cardioplegia, Neonatal Starter Bags and Heparin, products used directly in patient care at hospitals nationwide.
B. Braun cites continuity of supply and staff transition as priorities
Michael Parden, Chief Executive Officer of B. Braun of America, said the transition supports continued access to essential medications for patients and providers who depend on them. He noted that Quva has committed to providing employment opportunities for CAPS colleagues currently supporting local 503B sterile compounding operations.
QuVa operates 300,000 sq. ft. of manufacturing and distribution capacity
QuVa runs more than 200,000 sq. ft. of FDA-registered 503B manufacturing facilities in New Jersey and Texas, alongside 100,000 sq. ft. of forward distribution centers in Texas and Arizona. The company currently serves more than 3,500 hospitals and health system customers across the country with its sterile compounded medication portfolio.
QuVa CEO frames deal as investment in scarce manufacturing capacity
Stuart Hinchen, Chief Executive Officer of QuVa, said health systems depend on prepared medications that are essential to patient care but difficult to produce reliably at scale. He said the acquisition reflects continued investment in specialized products, manufacturing capabilities, quality systems, distribution infrastructure, technology and personnel needed to support these critical medication categories.